Category Archives: News

SOM Biotech at BIO Europe 2018

Europe’s largest annual life science partnering conference was held on November 5-7, 2018 in Copenhagen. BIO Europe serves as a forum for companies across the biotech value chain to meet and do business through one-to-one meetings, workshops, panels and exhibitions. The three-day conference drew over 4,000 industry attendees of high level networking, representing more than 2,000 companies from …

SOM Biotech invited to “Preferències” radio show

Each month, “Preferències” director and host Josep Maria Carrasco presents companies of special interest located at the PCB (Barcelona Science Park) on the RTVE Radio 4 channel. The radio show tackles all things innovative, from fashion to music, cinema to gastronomy, art to science. On September 27th, SOM Biotech CEO Dr. Raúl Insa was invited …

SOM Biotech joins Euronext TechShare Programme

Euronext, the first and largest pan-European stock exchange in the Eurozone, launched its fourth session of TechShare, the only European programme for non-listed companies dedicated to IPOs. The programme is an educational network designed to help fast-growing European tech companies understand the role of capital markets and how these high-potential businesses can help them reach the next stage …

Workshop on Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy

The 3rd Workshop on the Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy was held on September 7, 2018, coinciding with the World Duchenne Awareness Day. The workshop was organized by Duchenne Parent Project España and was focused on the research of the Muscular Dystrophies of Duchenne and Becker in Spain. Participants gathered at the Faculty of Biology of …

SOM Biotech at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology 2018

BIT’s 16th Annual Congress of International Drug Discovery Science and Technology (IDDST 2018) was held on 16th-18th August 2018 in Boston, Massachusetts with the theme “Rethinking the Next Big Things in Pharma Innovations”. The congress hosted leading scientists and professionals from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. SOM Biotech CEO …

First patient recruited to SOMCT02 Huntington’s disease trial

The SOMCT02 trial has recruited its first patient on 8th August 2018 at the Hospital Clínic de Barcelona, under the leadership of Dr. Esteban Muñoz. This indicates that the trial is now fully underway. SOMCT02 is a Phase 2a proof-of-concept and is designed as a randomized, double-blind, placebo-controlled, 2-arm, 27-week study to evaluate the safety and efficacy of …

SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington’s Disease Patients

BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 17, 2018 — SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs for orphan indications in the Central Nervous System, has announced today the successful initiation of Phase 2a clinical trial of its repurposed compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease. The Principal Investigator of the study is …

SOM Biotech presents to the BIO.NRW Investors Circle

This year, SOM Biotech was invited to present to the Investors Circle of the Business Angel Network of BIO.NRW on the 9th of July in Dusseldorf, Germany. SOM Biotech CEO Dr. Raúl Insa presented the company, highlighting its proven business model to the attending investors. The presentation platform is held three to four times a year in a strictly confidential …